Clinical Trials Browser

Phase 2 × Withdrawn × Alemtuzumab × Clear all

NCT00129753 2018-11-08

Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease

Phase 2 Withdrawn

Hodgkin Disease, Lymphoma, Recurrence

NCT00081068 2013-01-08

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Phase 2 Withdrawn

Lymphoma, Waldenstrom Macroglobulinemia